1. Liposomes of irinotecan or irinotecan hydrochloride, characterized in that these liposomes contain irinotecan or irinotecan hydrochloride, neutral phospholipid and cholesterol, and the mass ratio of cholesterol to neutral phospholipid is 1: 3-5.2. Liposomes according to claim 1, characterized in that the mass ratio of neutral phospholipid to irinotecan or irinotecan hydrochloride is: 3. Liposomes according to claim 1, characterized in that the neutral phospholipid comprises hydrogenated soybean phosphatidylcholine. Liposomes according to claim 3, characterized in that the neutral phospholipid is a hydrogenated soybean phosphatidylcholine. Liposomes according to claim 1, characterized in that the ratio of cholesterol to neutral phospholipid is 1: 3.5-4.5, preferably 1: 4.6. Liposomes according to claim 1, characterized in that they are obtained by the ion gradient method. Liposomes according to claim 6, characterized in that they have an ionic gradient formed by a buffer between the internal aqueous phase and the external aqueous phase of liposomes, preferably the internal aqueous phase of liposomes has a higher ionic concentration than the external aqueous phase. Liposomes according to claim 1, characterized in that they further comprise a lipid derivative of a hydrophilic polymer, preferably polyethylene glycol2000-distearoylphosphatidylethanolamine (DSPE-PEG). The liposomes of claim 8, characterized in that the mass ratio of the lipid derivative of the hydrophilic polymer to irinotecan or irinotecan hydrochloride is 0.2-0.4.10. Liposomes according to any one of claims 1 to 9, characterized in that they additionally contain a charged phospholipid, which is selected1. Липосомы иринотекана или иринотекана гидрохлорида, характеризующиеся тем, что эти липосомы содержат иринотекан или иринотекан гидрохлорид, нейтральный фосфолипид и холестерин, и массовое отношение холестерина к нейтральному фосфолипиду составляет 1:3-5.2. Липосомы по п.1, характеризующиеся тем, что
